Business
Resverlogix Appoints Bradley Glass to Board of Directors
Calgary, Alberta--(Newsfile Corp. - November 18, 2025) - Resverlogix Corp. (TSX: RVX) (...
About this update from Resverlogix Corp.
[{"type":"text","content":"Resverlogix Appoints Bradley Glass to Board of DirectorsCalgary, Alberta--(Newsfile Corp. - November 18, 2025) - Resverlogix Corp. (TSX: RVX) (\"Resverlogix\", or the \"Company\") today announces the appointment of Mr. Bradley Glass, J.D. as a member of the Company's board of directors.Mr. Glass has served as the General Counsel of Hepalink USA, Inc. and its subsidiaries (\"Hepalink\") for the past four years. In that role, Mr. Glass is responsible for managing all of Hepalink's U.S. legal issues. Prior to joining Hepalink, Mr. Glass was in private law practice for over twenty years and advised, counseled, and represented clients all over the United States on a broad range of matters. Mr. Glass has represented and litigated numerous matters in federal, state, and local courts and administrative tribunals on a wide range of complex business and regulatory matters. Mr. Glass is a graduate of Wabash College and the Indiana University School of Law.\"We are very pleased to welcome Bradley Glass to Resverlogix's board of directors,\" said Donald McCaffrey, Chairman and CEO. \"Bradley's decades of legal and business experience will bring a valuable perspective to our Board. We look forward to Bradley's insights and contributions in advancing our strategic objectives.\"\"I'm thrilled to join the board and look forward to supporting Resverlogix's progress,\" said Mr. Glass. \"This appointment reflects Resverlogix and Hepalink's common goal of apabetalone's successful development.\"About ResverlogixFounded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease.Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state.The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions.Resverlogix has partnered with EVERSANA™, the pioneer of next generation commercial services to the global life sciences indu...